Company intelligence / Profile preview
Onchilles Pharma
San Diego, California, United Statesonchillespharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Onchilles has demonstrated that its lead candidate N17350 selectively kills tumor cells—including chemotherapy-resistant ones—while sparing healthy immune cells. Preclinical data show efficacy across multiple tumor types and patient-derived models. First-in-human clinical trials are planned for late 2025.
- Therapeutic areas
- Oncology
- Modalities
- Biologics (protein-based therapeutics)Monoclonal antibodies (for TAM modulation)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Onchilles Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Onchilles Pharma.